Travere Therapeutics has transitioned into a rare disease commercial platform, driven by FILSPARI’s growth in IgAN and recent FSGS approval. More on TVTX stock.

Wanna see a trick? Give us any topic and we can tie it back to the economy. At Planet Money, we explore the forces that shape our lives and bring you along for the ride. Don't just understand the ...

Five independent security disclosures in a single week point to the same gap: AI agent permissions, not AI agent capabilities, are the problem enterprises haven’t solved. If you can only read one tech ...